Myovant Sciences Ltd. (MYOV) Can’t Be More Hot. Just Reaches All Time High

March 14, 2018 - By Vivian Park

The stock of Myovant Sciences Ltd. (NYSE:MYOV) reached all time high today, Mar, 14 and still has $19.97 target or 3.00 % above today’s $19.39 share price. This indicates more upside for the $1.18 billion company. This technical setup was reported by If the $19.97 PT is reached, the company will be worth $35.49 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 0.83% or $0.16 during the last trading session, reaching $19.39. About 51,691 shares traded or 70.09% up from the average. Myovant Sciences Ltd. (NYSE:MYOV) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Myovant Sciences Ltd. (NYSE:MYOV) to report earnings on June, 13. After $-0.70 actual EPS reported by Myovant Sciences Ltd. for the previous quarter, Wall Street now forecasts -11.43 % EPS growth.

More notable recent Myovant Sciences Ltd. (NYSE:MYOV) news were published by: which released: “Myovant Sciences Secures Flexible Financing Commitments of up to $140 Million” on October 16, 2017, also with their article: “Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with …” published on June 29, 2017, published: “Myovant Sciences Provides Corporate Update and Reports Financial Results for …” on November 13, 2017. More interesting news about Myovant Sciences Ltd. (NYSE:MYOV) were released by: and their article: “Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1% August 18, 2017” published on August 18, 2017 as well as‘s news article titled: “Myovant Bolsters Executive Team with Key Management Appointments” with publication date: July 19, 2017.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $1.18 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: